share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外国发行人报告
SEC announcement ·  03/14 16:08
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has received a notification from the Nasdaq Listings Qualifications Department on March 11, 2024, indicating that the company's American Depositary Shares (ADSs) have been trading below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market for the past thirty consecutive business days. This notice does not immediately affect the listing or trading of RedHill's ADSs. The company has until September 9, 2024, to regain compliance with the minimum bid price requirement, as per Nasdaq Listing Rule 5810(c)(3)(A). RedHill's ADSs will continue to trade on The Nasdaq Capital Market, and its operations remain unaffected. RedHill is considering options to address the deficiency and may be eligible for an additional 180-day compliance period if necessary conditions are met.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has received a notification from the Nasdaq Listings Qualifications Department on March 11, 2024, indicating that the company's American Depositary Shares (ADSs) have been trading below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market for the past thirty consecutive business days. This notice does not immediately affect the listing or trading of RedHill's ADSs. The company has until September 9, 2024, to regain compliance with the minimum bid price requirement, as per Nasdaq Listing Rule 5810(c)(3)(A). RedHill's ADSs will continue to trade on The Nasdaq Capital Market, and its operations remain unaffected. RedHill is considering options to address the deficiency and may be eligible for an additional 180-day compliance period if necessary conditions are met.
专业生物制药公司RedHill Biopharma Ltd. 已于2024年3月11日收到纳斯达克上市资格部门的通知，表明该公司的美国存托股票（ADS）在过去连续三十个工作日中一直低于继续在纳斯达克资本市场上市的每股1.00美元的最低要求。本通知不会立即影响RedHill广告的上市或交易。根据纳斯达克上市规则第5810（c）（3）（A），该公司必须在2024年9月9日之前重新遵守最低出价要求。RedHill的ADS将继续在纳斯达克资本市场上交易，其业务不受影响。RedHill正在考虑解决这一缺陷的备选方案，如果满足必要条件，可能有资格再延长180天的合规期。
专业生物制药公司RedHill Biopharma Ltd. 已于2024年3月11日收到纳斯达克上市资格部门的通知，表明该公司的美国存托股票（ADS）在过去连续三十个工作日中一直低于继续在纳斯达克资本市场上市的每股1.00美元的最低要求。本通知不会立即影响RedHill广告的上市或交易。根据纳斯达克上市规则第5810（c）（3）（A），该公司必须在2024年9月9日之前重新遵守最低出价要求。RedHill的ADS将继续在纳斯达克资本市场上交易，其业务不受影响。RedHill正在考虑解决这一缺陷的备选方案，如果满足必要条件，可能有资格再延长180天的合规期。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息